JP2023512287A - 化学防護効果を提供するための組成物及び方法 - Google Patents

化学防護効果を提供するための組成物及び方法 Download PDF

Info

Publication number
JP2023512287A
JP2023512287A JP2022546650A JP2022546650A JP2023512287A JP 2023512287 A JP2023512287 A JP 2023512287A JP 2022546650 A JP2022546650 A JP 2022546650A JP 2022546650 A JP2022546650 A JP 2022546650A JP 2023512287 A JP2023512287 A JP 2023512287A
Authority
JP
Japan
Prior art keywords
cells
gcl
cell
gclm
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022546650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512287A5 (https=
Inventor
セルハト・グムルーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2023512287A publication Critical patent/JP2023512287A/ja
Publication of JP2023512287A5 publication Critical patent/JP2023512287A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02002—Glutamate-cysteine ligase (6.3.2.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022546650A 2020-01-31 2021-02-01 化学防護効果を提供するための組成物及び方法 Pending JP2023512287A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062968906P 2020-01-31 2020-01-31
US62/968,906 2020-01-31
PCT/US2021/016041 WO2021155351A1 (en) 2020-01-31 2021-02-01 Compositions and methods for providing chemoprotective effects

Publications (2)

Publication Number Publication Date
JP2023512287A true JP2023512287A (ja) 2023-03-24
JP2023512287A5 JP2023512287A5 (https=) 2024-02-08

Family

ID=77079986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546650A Pending JP2023512287A (ja) 2020-01-31 2021-02-01 化学防護効果を提供するための組成物及び方法

Country Status (4)

Country Link
EP (1) EP4096649A4 (https=)
JP (1) JP2023512287A (https=)
CN (1) CN115605084A (https=)
WO (1) WO2021155351A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020195A1 (en) * 1992-04-01 1993-10-14 Fox Chase Cancer Center Method and recombinant cells for providing increased resistance of hematopoietic progenitor cells to toxicity of chemotherapeutic agents
US20190269734A1 (en) * 2017-11-15 2019-09-05 Weird Science Llc Methods and compositions for non-myeloablative bone marrow reconstitution

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
WO2015009884A1 (en) * 2013-07-18 2015-01-22 The Hamner Institutes Cell culture media formulations comprising an activator of nad-dependent protein deacteylase and ueses thereof
CA3106403A1 (en) * 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020195A1 (en) * 1992-04-01 1993-10-14 Fox Chase Cancer Center Method and recombinant cells for providing increased resistance of hematopoietic progenitor cells to toxicity of chemotherapeutic agents
US20190269734A1 (en) * 2017-11-15 2019-09-05 Weird Science Llc Methods and compositions for non-myeloablative bone marrow reconstitution

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MUTAGENESIS, vol. 24, JPN6024051966, 2009, pages 211 - 224, ISSN: 0005492064 *

Also Published As

Publication number Publication date
EP4096649A4 (en) 2024-04-17
CN115605084A (zh) 2023-01-13
WO2021155351A1 (en) 2021-08-05
EP4096649A1 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
Toro et al. TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice
JP7787265B2 (ja) 非骨髄破壊的な骨髄再構成のための方法および組成物
US8124377B2 (en) Method of producing TAT-HOXB4H
JP2021522837A (ja) 造血幹細胞移植のための組成物及び方法
US20200009194A1 (en) Systems and methods for hematopoietic cell expansion utilizing hydrogels
MXPA05003057A (es) Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
JP2021505172A (ja) 造血幹細胞及び前駆細胞を動員させるための投薬レジメン
ES2299590T3 (es) Uso medico de celulas madre que expresan vegfr-1.ng vegfr-1.
US12390491B2 (en) Compositions and methods for providing chemoprotective effects
JP2023512287A (ja) 化学防護効果を提供するための組成物及び方法
US20250154466A1 (en) Combination bcl11a enhancer editing
US20220401481A1 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
Vassilev et al. Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors
US20230414565A1 (en) Compositions and methods for treating hematological malignancies
US20070244037A1 (en) Human Chemokine HCC-1 Polypeptides To Improve Stem Cell Transplantation
Levesque et al. The role of mesenchymal stem cells in hematopoiesis
Vasam Angiotensin-(1-7): A Target for Stem Cell Mobilopathy and Vascular Repair in Diabetes
Peled et al. Role of the CXCR4/CXCL12 Axis in Hematopoietic Stem Cell Trafficking
Yannaki et al. A mobilization study in the thalassemic mouse model: Implications for human gene therapy of thalassemia
US20080200419A1 (en) Splicing Variant of TGF-beta2 and Uses Thereof
Corbí Pathogen recognition by dendritic cells: Role of C-type lectins
HK1130290B (en) Method of producing recombinant tat-hoxb4h protein for use as a stimulant of hematopoiesis in vivo

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250620

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251007